Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A View From Europe

American Journal of Kidney Diseases

Volumn 50, Issue 3, 2007, Pages 358-361

  Macdougall, Iain C ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; COST BENEFIT ANALYSIS; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG COST; DRUG MARKETING; DRUG MEGADOSE; EDITORIAL; EUROPE; FOOD AND DRUG ADMINISTRATION; FUNDING; HEALTH CARE COST; HEALTH CARE FACILITY; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MEDICAL PRACTICE; ORGANIZATION AND MANAGEMENT; REIMBURSEMENT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AMBULATORY CARE FACILITIES; ANEMIA; EPOETIN ALFA; EUROPE; HEMATINICS; HUMANS; OWNERSHIP; RENAL DIALYSIS;

EID: 34548020783     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.07.010     Document Type: Editorial

References (12)

1. Thamer M., Zhang Y., Kaufman J., Cotter D., Dong F., and Hernan M.A. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA 297 (2007) 1667-1674
2. Pisoni R.L., Bragg-Gresham J.L., Young E.W., et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44 (2004) 94-111
3. Kaufman J.S., Reda D.J., Fye C.L., et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 339 (1998) 578-583
4. Covic A., Locatelli F., Macdougall I.C., and Wiecek A. Achievement of EBPG targets in Eastern and Western Europe: ORAMA preliminary results. World Congress of Nephrology 2007 Book of Abstracts (2007) 293 Rio de Janeiro, Brazil, April 21-25, (abstr)
5. Casadevall N., Nataf J., Viron B., et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346 (2002) 469-475
6. Gershon S.K., Luksenburg H., Cote T.R., and Braun M.M. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 346 (2002) 1584-1586
7. The Renal Association. UK Renal Registry: The Eighth Annual Report (2005) Bristol, United Kingdom, December
8. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 335 (2006) 2085-2098
9. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 335 (2006) 2071-2084
10. Zhang Y., Thamer M., Stefanik K., Kaufman J., and Cotter D.J. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44 (2004) 866-876
11. Besarab A., Bolton W.K., Brown J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
12. Macdougall I.C., Roberts D.E., Coles G.A., and Williams J.D. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet 20 (1991) 99-113